We examined the in vivo metabolic effects of vanadyl sulfate (VS) in non-insulin-dependent diabetes mellitus (NIDDM). Six NIDDM subjects treated with diet and/or sulfonylureas were examined at the end of three consecutive periods: placebo for 2 wk, VS (100 mg/d) for 3 wk, and placebo for 2 wk. Euglycemic hyperinsulinemic (30 mU/ m2 * min) clamps and oral glucose tolerance tests were performed at the end of each study period. Glycemic control at baseline was poor (fasting plasma glucose 210±19 mg/ dl; HbAlc 9.6±0.6%) and improved after treatment (181±14 mg/dl [P < 0.05],8.8±0.6%, [P < 0.002]); fasting and post-glucose tolerance test plasma insulin concentrations were unchanged. After VS, the glucose infusion rate during the clamp was increased (by -88%, from 1.80 to 3.38 mg/kg* min, P < 0.0001). This improvement was due to both enhanced insulin-mediated stimulation of glucose uptake (rate of glucose disposal [Rd.], +0.89 mg/kg min) and increased inhibition of HGP (-0.74 mg/kg r min) (P < 0.0001 for both). Increased insulin-stimulated glycogen synthesis (+0.74 mg/kg min, P < 0.0003) accounted for > 80% of the increased Rd after VS, and the improvement in insulin sensitivity was maintained after the second placebo period. The K. of skeletal muscle glycogen synthase was lowered by -30% after VS treatment (P < 0.05).
Introduction
Non-insulin-dependent diabetes mellitus (NIDDM) ' is characterized by impaired sensitivity to insulin, particularly in skeletal muscle and liver (1, 2) . Oral drug therapy aimed at controlling hyperglycemia in NIDDM often fails, and most patients require insulin treatment late in the course of their disease. This progressive deterioration in glucose metabolism is due, in part, to worsening insulin sensitivity which may be ameliorated by the glucose-lowering effect of exogenous insulin therapy (3) , but a number of side effects and complications accompany insulin therapy. Therefore, agents which could augment insulin sensitivity at the level of muscle and liver may be useful in treatment of NIDDM.
The insulinomimetic properties of vanadium compounds have been well documented in vitro and in vivo (4) (5) (6) (7) (8) . Among its several biologic effects, vanadium has been shown to stimulate glucose uptake, glycogen synthesis, and glucose oxidation in adipose cells and in skeletal muscle (4) (5) (6) . As early as 1899, Lyonnet et al. (9) reported a decrease in glycosuria in two patients with diabetes given sodium vanadate. Heyliger et al. (7) first demonstrated potent in vivo effects of vanadium on carbohydrate metabolism in experimental diabetes. More recently, we have demonstrated that vanadate normalized insulinmediated glucose disposal in 90% partially pancreatectomized diabetic rats, in part due to restoration of glycogen synthetic rate in skeletal muscle (8) . Vanadate treatment also increased the basal activity of the insulin receptor tyrosine kinase, an effect not observed simply with correction of hyperglycemia by phlorizin (10) . Taken together with previous in vitro studies, these data suggest that vanadium ameliorates hyperglycemia via its insulinomimetic effects on hepatic and peripheral glucose metabolism.
Due to the lack of information on the effectiveness of vanadium salts in human diabetes mellitus, we undertook to study the effects of small oral doses of vanadyl sulfate in NIDDM. Vanadyl sulfate was the compound chosen because it is a form of vanadium not previously associated with overt short-term toxicity (11) (12) (13) . In view of data which indicate that vanadium augments insulin sensitivity in animals, we chose to study NIDDM patients in poor metabolic control who were not using insulin in a masked, placebo-controlled study design. We sought to evaluate a putative mechanism of action of the agent by examining skeletal muscle glycogen synthase activity and whole-body glucose metabolism during euglycemic hyperinsulinemic clamps. Finally, since vanadium compounds may accumulate in several tissues and exert residual biologic effects for prolonged periods in diabetic rats (14, 15) , we studied subjects after a 2-wk baseline placebo period, after 3 wk of vanadyl sulfate treatment, and after a second 2-wk placebo period.
Methods

Subjects
Six subjects with NIDDM were recruited for study (Table I) . They were generally in good health, had stable NIDDM diagnosed for at least Body composition. To estimate fat-free mass, body composition was measured after the first placebo period at week 2 using a bolus injection of 3H20 (18) . Fat-free body mass was estimated from total body water determinations, assayed by administration of tritiated water (40 Plasma tritiated water specific activity was determined by liquid scintillation counting of the protein-free supernatant (Somogyi filtrate) before and after evaporation to dryness. Because tritium on the C-3 position of glucose is lost to water during glycolysis, it can be assumed that plasma tritium is present either in tritiated water or 3H-3-glucose (19, 20) . This method to estimate whole-body glycolysis has been validated recently under hyperinsulinemic conditions (21). Plasma insulin, Cpeptide, and glucagon were determined by radioimmunoassay. Plasma FFA was measured by a colorimetric method, and plasma lactate was measured by using an enzymatic spectrophotometric assay (22) . Plasma vanadate concentrations were measured by atomic absorption spectrometry (23) . For indirect calorimetry, air flow, 02, and CO2 concentrations in the expired and inspired air were measured by a computerized opencircuit system (Delta Trak; Sensormedics Corp., Yorba Linda, CA).
Urinary nitrogen was measured by the Kjeldahl procedure (24) . HbAj, was measured by ion exchange chromatography with an upper limit of normal of 6.2%, and serum fructosamine was measured by a spectrophotometric technique. Plasma cortisol and growth hormone concentrations were measured by radioimmunoassay (25) .
Glycogen synthase
Muscle glycogen synthase activity was measured by a modification (8, 21 ) of the method of Thomas et al. (26) and is based on the measurement of the incorporation of radioactivity into glycogen from UDP-[U-'4C] -glucose. Tissue samples (5-10 mg) were homogenized in 1.0 ml of Tris/HCl buffer, pH 7.8, containing 10 mM EDTA, 5 mM dithiothreitol, 50 mM NaF, and 2.5 g/liter rabbit liver glycogen type HI. The homogenate was centrifuged at 3,000 g for 30 min (at 4°C), and the supernatant was used for glycogen synthase assay by measuring the incorporation of UDP-[U-14C] -glucose into glycogen at 30°C. Synthase activity was assayed in the presence of 0.11 and 0.22 mM glucose-6-phosphate. Total enzyme activity was measured in the presence of 7.2 mM glucose-6-phosphate. For the kinetic analysis the assay was conducted at final concentrations of 0.003, 0.017, 0.033, 0.090, 0.330, and 1.4 mM UDPG; the data were linearized as Eadie-Hofstee plots and fitted using a linear regression model. The K. for UDPG is the reciprocal of the slope whereas V,, is the y-intercept divided by the slope. Fractional velocity is calculated as the ratio of synthase activity at 0.11 and 0.22 mM glucose-6-phosphate over total enzyme activity (7.2 mM glucose-6-phosphate) at physiological (5-50 IsM) UDPG concentrations (21).
Glycogen phosphorylase
Muscle glycogen phosphorylase activity was estimated based on the measurement of the incorporation of '4C into glycogen from labeled glucose-l-phosphate (27) . Glycogen phosphorylase a, the active phosphorylated enzyme, was assayed in the absence of AMP, and phosphorylase b, the total enzyme activity, was assayed in the presence of 5 mM AMP. Tissue homogenates (5-10 mg) were prepared as described above. The supernatant was used for glycogen phosphorylase assay by measuring the incorporation of '4C-glucose-1-phosphate into glycogen at 30°C in a mixture containing 33 mM Mes, 200 mM KF, 0.45% mercaptoethanol, 15 mM glucose-i-phosphate (50 jiCi/mmol), and 3.4 mg/ml glycogen. Phosphorylase b was assayed in the same manner except that the mixture contained 100 mM glucose-l-phosphate (6 tCi/ mmol), 13 .4 mg/ml glycogen, and 5 mM AMP.
Calculations
Fasting plasma glucose during each study period was calculated by averaging fasting plasma glucose values measured on the mornings of the OGTT and the euglycemic clamp (before insulin infusion). These values were not significantly different from each other. Glucose turnover during clamp experiments was calculated using Steele's equation (28) . Rates of glycolysis from plasma glucose were estimated from the increment per unit time in tritiated water (dpm/mi * min) x body water mass (ml)/3H-3-glucose specific activity (dpm/mg) as previously validated (19, 21) . Glycogen synthetic rates were estimated as the difference between Rd (rate of glucose disposal) and glycolysis. Carbohydrate oxidation was calculated from 02 consumption and CO2 production (corrected for protein oxidation) with the equations of Lusk (29) . Data for glucose turnover, carbohydrate oxidation, and plasma hormone and substrate concentrations represent the mean values during the last 60 min of the basal period and the final 60 min of hyperinsulinemia. To convert mg/kg min to Amol/kg min multiply by 5 .551.
Statistical analyses
Repeated measurement analyses of the variables were performed using PROC MIXED (SAS/STAT User's Guide, Release 6.07, Cary, NC). The random effect considered in this mixed model is the error measurement of the individual subject, and the within-individual fixed effects are stage of study (placebo 1, vanadyl sulfate, placebo 2) and the specific time points during physiologic (clamp and OGGT) studies in each stage. For laboratory data with one observation per study period per subject, only the stage effect is considered as a fixed effect. Compound symmetry variance-covariance structure was assumed in the analysis. The an average of -1 g/dl comparing the first placebo with either vanadium (P < 0.05) or placebo 2 (P < 0.02). This was accompanied by parallel decreases in hematocrit (Table II) but no change in red cell indices. Serum iron and iron saturation declined minimally as well (not shown). In four patients hematologic tests were repeated 3 wk after completion of the study; hemoglobin concentration remained comparable with values in the vanadyl sulfate treatment period. The effect of vanadium treatment on dynamic glycemic responses was assessed during OGTT performed after each treatment phase (Fig. 2) . While there was a decrease in fasting plasma glucose, the glycemic response during OGTT was essentially unchanged during vanadyl sulfate treatment (Fig. 2) . Similarly, there were no significant changes in the insulin secretory response as reflected by either plasma insulin or plasma Cpeptide concentrations after oral glucose. Fasting plasma insulin and C-peptide levels were similar during treatment and placebo periods. Plasma glucagon concentrations were not altered by vanadyl sulfate in either fasting (172±12 vs 156±13 pg/ml, placebo 1 and vanadyl sulfate, respectively, P = NS) or postglucose challenge samples (158±8 vs 153±10 pg/ml, placebo 1 and vanadyl sulfate at 60 min, respectively, P = NS).
We investigated the mechanism of action of vanadyl sulfate on insulin-mediated processes during euglycemic hyperinsulinemic clamps (Fig. 3) . Before the initiation of the euglycemic clamp, plasma glucose was maintained at near-euglycemic concentrations by a variable infusion of insulin. Insulin infusion rates averaged 21±3, 18±2, and 20±2 mU/m2 min (P = NS) 2504 Cohen et al. Time (min) Figure 3 . Plasma glucose, plasma insulin, glucose specific activity, and glucose infusion rate during clamp studies after first placebo period, vanadyl sulfate treatment, and second placebo period (see Fig. 2 Fig. 3 ). The coefficient of variation for plasma glucose concentrations during the clamps averaged 2.5% in all three study sets. In addition, the plasma glucose specific activities for 3H-3-glucose were maintained at stable and comparable levels (Fig. 3) . The glucose infusion rate required to maintain euglycemia ( Figs. 1 and 3 pumol/kg min during the three study periods (P = NS). Glucose turnover averaged over the final 60 min of the clamps is shown in Fig. 4 . At the end of the first placebo period, hyperinsulinemia resulted in suppression of HGP by -55%. With vanadyl sulfate treatment, glucose output was nearly completely suppressed (P < 0.0001). This heightened sensitivity of the liver to insulin was maintained in the second placebo period (P < 0.0003 vs first placebo period). Similarly, insulinstimulated glucose uptake was significantly greater during vanadium treatment (P < 0.0001) and remained improved after reinstitution of placebo (P < 0.0001). The increase in glucose disposal observed during and after discontinuation of vanadyl sulfate was largely accounted for by an increase in glycogen synthesis (P < 0.0003), while plasma-derived glucose flux through glycolysis was minimally increased only during the second placebo period (P < 0.001).
Carbohydrate oxidation estimated from indirect calorimetry before initiation of the clamp was similar in all study periods, averaging 1.50±0. 26 Omol/kg min], P = NS).
Plasma FFA and lactate concentrations are depicted in Fig.  5 . Basal plasma FFA concentrations were similar in all study periods. At the end of the first placebo period, hyperinsulinemia resulted in no change in plasma FFA (0.36±0.08 mM). A significant decrease in FFA concentrations with hyperinsulinemia was observed during vanadium administration (0.23±0.03 mM [P < 0.0001]) which persisted despite reinstitution of placebo (0.22±0.03 mM [P < 0.0001]). Basal plasma lactate concentrations were also similar in all study periods. During the last 60 min of hyperinsulinemia, plasma lactate was significantly lower after vanadyl sulfate treatment (1.10±0.11 mM [P < 0.004]) and after reinstitution of placebo (1.04±0.14 mM [P < 0.0002]) compared with the first placebo period (1.30±0.10 mM). Plasma cortisol (17±3, 13± 1, and 15±1 M~g1 dl) and growth hormone (0.7+0.3, 2.3±0.9, and 2.2±1.5 ng/ ml) were similar in all three study periods (P = NS for both).
Skeletal muscle glycogen synthase and phosphorylase activities are shown in Table III . Physiologic hyperinsulinemia (clamp) did not significantly decrease the Km for UDPglucose or increase fractional velocity in NIDDM subjects. However, both basal and post-clamp glycogen synthase kinetics were significantly improved during vanadyl sulfate treatment compared with the first placebo period (Table III) . Thus, the basal muscle glycogen synthase Km was decreased by 26-29% after vanadyl treatment compared with placebo (P < 0.05). The significant decrease in Kn at the end of the insulin clamp study was completely accounted for by the improved affinity for UDPglucose under basal conditions. The Km for UDPglucose of muscle glycogen synthase was inversely correlated with the in vivo rates of glycogen synthesis (r2 = 0.58). Muscle glycogen phosphorylase activity was not affected by treatment (Table III) .
Discussion
We examined the metabolic effects of vanadyl sulfate in moderately obese, conventionally controlled NIDDM subjects with significant baseline impairment of insulin sensitivity (both hepatic and peripheral). Over the course of the screening run-in period (6 wk) and baseline placebo period (2 wk), patients remained hyperglycemic (HbA1, 9.7±0.5 and 9.6±0.6% at screening and at the end of the first placebo period, respectively) on unchanged treatment regimens. Vanadyl sulfate treatment for 3 wk resulted in significantly improved fasting plasma glucose and HbA1, levels (8.8±0.6%). This was observed despite lack of significant improvement in either serum fructosamine, plasma glucose, and insulin responses during OG1T, and in the Though vanadium compounds have been given therapeutically as antiseptics, antituberculous agents, and hematinics (30) , there is little systematic data in humans. Vanadium did not appear to be overtly toxic, since it was often used in relatively large doses and for prolonged periods of time (31, 32) . The comparison with animal studies is complicated by the large differences in the administered dose and plasma vanadium levels. In fact, the minimally effective dose of vanadyl sulfate in rodents (-125 mg/kg/d) was -100-fold higher than that used in the present study (12, 14, 15) , and the plasma vanadate concentration was -10-fold lower in our patients compared with vanadium-treated diabetic rats (7, 15) . Results of previous rat studies examining gastrointestinal and hematological effects of vanadium compounds have varied (23, 33, 34) . While a recent long-term (1 yr) study of nondiabetic and streptozotocindiabetic rats with vanadyl sulfate failed to demonstrate any significant changes in hematological indices at doses -100-fold higher than used in the present study (13) , increases in serum urea and creatinine concentrations and alterations in hepatic function after vanadium treatment have also been reported by some (35) (36) (37) but not others (13, 23, 33, (38) (39) (40) . Increased mortality and weight loss has been reported recently in streptozotocin-diabetic rats treated with vanadate (36) . The use of variably insulinopenic and dehydrated animals in combination with the marked decrease in fluid intake which follows the inclusion of vanadium in drinking solution may explain some of the discrepancies on the toxic effects of the trace element in rodents (13, 23, 33, (35) (36) (37) (38) (39) (40) . Finally, in vitro studies have demonstrated that vanadium ions may promote genetic alterations and mitogenic effects in cultured cells (41, 42) . Though neither the short-term toxicity nor the long-term effects of the agent have been systematically studied in humans, taken as a whole these data raise concerns about the potential use of these agents for long-term therapy of NIDDM. Since vanadium compounds are widely available without prescription, their longterm toxicity and effectiveness should be thoroughly investigated.
Among its several biologic effects, vanadium (> 200 AM) mimics insulin action in vitro in several isolated cell systems (4) (5) (6) . In vivo studies suggesting an effect of vanadium in diabetes date as early as 1899 when Lyonnet et al. (9) reported a decrease in glycosuria in two diabetic patients given sodium vanadate. Subsequent studies in insulin-deficient streptozotocindiabetic rats (7, 39, 43, 44) and partially pancreatectomized rats (8, 45) as well as in obese hyperinsulinemicfa/fa rats (39) have borne out this antidiabetic effect. Recent studies from our laboratory demonstrated that the normalization of plasma glucose in 90% pancreatectomized rats by vanadate treatment caused a marked improvement in skeletal muscle glycogen synthesis independent of the correction of hyperglycemia (8) . Our present results confirm these observations in the rat and suggest that, in humans as well, vanadium exerts significant effects on glucose uptake and glycogen synthesis. In these insulin-resistant subjects with NIDDM, we observed significant and persistent improvement in glucose uptake and glycogen synthase activation by insulin. An enhanced suppression of lipolysis paralleled the improvement in glucose utilization.
It should be noted that our previous studies in rats did not examine the effect of vanadium on insulin-mediated inhibition of HGP since only maximal insulin response was examined (8, 45) . However, Blondel et al. (44) reported improved in vivo hepatic insulin action in vanadate-treated streptozotocin-diabetic rats, and a decline in gluconeogenesis has been suggested secondary to decreased expression of the P-enolpyruvate carboxykinase (PEPCK) gene and increased glycolysis in the liver (46) (47) (48) The mechanism of action of vanadium on altered carbohydrate metabolism remains unclear. Recent studies in the rat provide conflicting evidence as to whether the vanadium-induced anorexia and/or weight loss accounts for its amelioration of experimental diabetes (49) . Importantly, the potent effects of vanadate treatment on plasma glucose concentration and insulin action were also observed in pair-fed 90% pancreatectomized (8) and obese hyperinsulinemicfa/fa rats (39) . In our subjects, anorexia was not observed, and resting energy expenditure was not augmented by vanadate. Furthermore, we are not aware of published data that indicate that the minimal decline in body weight we observed during treatment can explain the marked changes in glucose metabolism. Other postulated effects include a reduction in Na+ -dependent glucose transport in small intestine (50) . Previous studies from our laboratory indicated that vanadate treatment in diabetic rats improved the basal insulin receptor tyrosine kinase activity with no change in insulin-stimulated activity (10) . Other in vitro studies have suggested that vanadate may exert effects through activation of mitogen-activating protein kinase activity independent of insulin receptor autophosphorylation (51) . The increased basal activation of skeletal muscle glycogen synthase observed in this study is consistent with a preliminary report on the activation of basal mitogen-activating protein kinase activity in circulating monocytes in NIDDM patients treated with vanadate for 2 wk (52). However, in this study, 2 wk of treatment with Na-metavanadate did not show significant changes in fasting plasma glucose, HbAI, or serum fructosamine in four NIDDM subjects.
Whether the in vivo actions of vanadyl sulfate in NIDDM can be attributed to these or other mechanisms cannot be determined from this study. As with previous studies (7, 8, 38, 43) , we can be confident that the improvement in glucose metabolism was not due to an increase in plasma insulin concentrations since neither fasting nor post-OGTT plasma insulin or C-peptide concentrations were higher after 3 wk of vanadyl sulfate. However, since plasma insulin concentrations were not reduced in the setting of decreased hyperglycemia, it may be argued that there may have been some amelioration of glucose-induced insulin secretion, perhaps indirectly via reduction of glucose toxicity (53, 54) . In addition, there was no evidence that insulin counterregulatory hormones were decreased by treatment.
Finally, we found a remarkable persistence of the effects of vanadyl sulfate after discontinuation of the agent for 2 wk. These findings are consistent with studies that have documented the beneficial effects of vanadyl treatment for up to 13 wk after withdrawal of treatment in diabetic rats (14) . Though plasma vanadium concentrations remained detectable 2 wk after withdrawal, it is unlikely that the persistent effects were due solely to these residual circulating levels of the trace element. In vivo administration of vanadate or vanadyl sulfate to diabetic animals appears to require a lag time to manifest its effects on carbohydrate metabolism, and the tissue distribution of the element is widespread (23) . Indeed, though vanadate transport into intact cells is a relatively slow process, several in vitro effects on glucose metabolism have been observed within minutes (4-6). We observed virtually identical changes in glucose homeostasis in the clamps after the second placebo period as after vanadyl sulfate treatment, though we did not obtain skeletal muscle biopsies at this point of the study. Whether some of the longterm effects we observed are due to persistence of vanadium action per se or to the 3-wk improvement in carbohydrate and fat metabolism remains to be elucidated.
In summary, this study provides evidence for potent metabolic effects of vanadium in humans with NIDDM. 3 wk of treatment with a low, well-tolerated dose of vanadyl sulfate resulted in decreased fasting plasma glucose and HbA1" concentrations in the absence of increased plasma insulin concentration. During euglycemic clamp studies, the hepatic and peripheral responses to physiologic hyperinsulinemia were markedly improved. Importantly, these beneficial metabolic effects of vanadyl sulfate were sustained for at least 2 wk after discontinuation of treatment. These results underscore the need for further investigation to establish the safety and long-term effectiveness of vanadium compounds in human diabetes.
